Atif J Khan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1744543/publications.pdf

Version: 2024-02-01

168829 190340 3,381 126 31 53 h-index citations g-index papers 126 126 126 4625 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Examining the prevalence of homologous recombination repair defects in ER+ breast cancers. Breast Cancer Research and Treatment, 2022, 192, 649.	1.1	2
2	Bilateral Regional Nodal Irradiation Using Volumetric Modulated Arc Therapy: Dosimetric Analysis and Feasibility. Practical Radiation Oncology, 2022, 12, 189-194.	1.1	2
3	In Reply to Rabinovitch. Practical Radiation Oncology, 2022, 12, e243-e244.	1.1	О
4	Impact of clonal hematopoiesis on tumor control following radiation therapy Journal of Clinical Oncology, 2022, 40, 3145-3145.	0.8	0
5	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	3.0	38
6	10-Year Breast Cancer Outcomes in Women ≧5 Years of Age. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1007-1018.	0.4	14
7	Tolerability of Breast Radiotherapy Among Carriers of <i>ATM</i> Oncology, 2021, 5, 227-234.	1.5	5
8	Ultra-Short Fraction Schedules as Part of De-intensification Strategies for Early-Stage Breast Cancer. Annals of Surgical Oncology, 2021, 28, 5005-5014.	0.7	8
9	Salvage of locally recurrent breast cancer with repeat breast conservation using 45ÂGy hyperfractionated partial breast re-irradiation. Breast Cancer Research and Treatment, 2021, 188, 409-414.	1.1	9
10	Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer. Scientific Reports, 2021, 11, 12781.	1.6	17
11	Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 979-991.	0.4	11
12	Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation. JCO Oncology Practice, 2021, 17, e1055-e1074.	1.4	3
13	Are 5-Year Randomized Clinical Trial Results Sufficient for Implementation of Short-Course Whole Breast Radiation Therapy?. Practical Radiation Oncology, 2021, 11, 301-304.	1.1	4
14	Breast conservation among older patients with earlyâ€stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. Cancer, 2021, 127, 1749-1757.	2.0	11
15	Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation. Radiotherapy and Oncology, 2021, 165, 142-151.	0.3	11
16	Radiotherapy in the setting of hypersensitivity syndromes. Breast Journal, 2020, 26, 588-589.	0.4	0
17	Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. JAMA Network Open, 2020, 3, e2018790.	2.8	10
18	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2020, 108, 227-241.	0.4	24

#	Article	IF	Citations
19	Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. Breast Cancer Research and Treatment, 2020, 182, 355-365.	1.1	15
20	Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. Breast Cancer Research and Treatment, 2020, 180, 197-205.	1.1	11
21	Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints—Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States. Advances in Radiation Oncology, 2020, 5, 582-588.	0.6	86
22	5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 694-700.	0.4	24
23	Feasibility of Breast-Conservation Therapy and Hypofractionated Radiation in the Setting of Prior Breast Augmentation. Practical Radiation Oncology, 2020, 10, e357-e362.	1.1	4
24	Locoregional Management After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2020, 38, 2281-2289.	0.8	35
25	5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost. International Journal of Radiation Oncology Biology Physics, 2019, 105, 267-274.	0.4	13
26	Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. International Journal of Radiation Oncology Biology Physics, 2019, 105, 296-306.	0.4	37
27	A 3-Dimensional Mapping Analysis of Regional Nodal Recurrences in Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 583-591.	0.4	33
28	In Reply to Yadav and Gupta, and Hannoun-Levi etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 104, 700.	0.4	0
29	Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes. Advances in Radiation Oncology, 2019, 4, 447-452.	0.6	9
30	A Current Review of Spatial Fractionation: Back to the Future?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 177-187.	0.4	90
31	Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40ÂGy Is Well Tolerated and Locally Effective. International Journal of Radiation Oncology Biology Physics, 2019, 104, 859-866.	0.4	17
32	Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment. International Journal of Radiation Oncology Biology Physics, 2019, 104, 714-723.	0.4	44
33	Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-T Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 67-74.	0.4	48
34	Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. BMJ Open, 2019, 9, e025556.	0.8	60
35	Breast radiotherapy among <i>ATM</i> -mutation carriers Journal of Clinical Oncology, 2019, 37, 1504-1504.	0.8	2
36	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypNO after neoadjuvant chemotherapy (NC) Journal of Clinical Oncology, 2019, 37, TPS600-TPS600.	0.8	38

#	Article	IF	CITATIONS
37	The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2019, 10, 2824-2834.	0.8	18
38	The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy, 2018, 17, 154-170.	0.2	173
39	Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Annals of Surgical Oncology, 2018, 25, 154-163.	0.7	11
40	Risk of leptomeningeal carcinomatosis in patients with brain metastases treated with stereotactic radiosurgery. Journal of Neuro-Oncology, 2018, 136, 395-401.	1.4	22
41	Efficient double-scattering proton therapy with a patient-specific bolus. Physica Medica, 2018, 50, 1-6.	0.4	1
42	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC) Journal of Clinical Oncology, 2018, 36, TPS601-TPS601.	0.8	4
43	VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. Oncotarget, 2018, 9, 25833-25841.	0.8	36
44	Frequency of locoregional recurrence among locally advanced HER2-positive breast cancer treated with modern multimodality therapy Journal of Clinical Oncology, 2018, 36, e12604-e12604.	0.8	0
45	American Brachytherapy Society Task Group Report: Long-term control and toxicity with brachytherapy for localized breast cancer. Brachytherapy, 2017, 16, 13-21.	0.2	9
46	Underutilization of proton therapy in the treatment of pediatric central nervous system tumors: an analysis of the National Cancer Database. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1122-1125.	0.8	3
47	Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?. Gynecologic Oncology, 2017, 144, 299-304.	0.6	3
48	Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization. Advances in Radiation Oncology, 2017, 2, 588-596.	0.6	11
49	Cardiac Toxicity: The More We Learn, the Less We Know. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1162-1165.	0.4	9
50	Nation-Scale Adoption of Shorter Breast Radiation Therapy Schedules Can Increase Survival in Resource Constrained Economies: Results From a Markov Chain Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 97, 287-295.	0.4	23
51	External beam techniques to boost cervical cancer when brachytherapy is not an optionâ€"theories and applications. Annals of Translational Medicine, 2017, 5, 207-207.	0.7	32
52	Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial. Journal of Clinical Oncology, 2017, 35, 2037-2043.	0.8	87
53	The impact of early detection and intervention of breast cancerâ€related lymphedema: a systematic review. Cancer Medicine, 2016, 5, 1154-1162.	1.3	122
54	Randomized Phase 3 Trials of Accelerated Partial Breast Irradiation: A Trickle Before the Deluge. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1089-1091.	0.4	1

#	Article	IF	CITATIONS
55	Intraoperative Radiation Therapy in Breast Cancer: Still Not Ready for Prime Time. Annals of Surgical Oncology, 2016, 23, 1796-1798.	0.7	13
56	Consensus Statement on Proton Therapy inÂEarly-Stage and Locally Advanced Non–Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 505-516.	0.4	125
57	The Radiobiology of Breast Radiotherapy. , 2016, , 39-52.		0
58	Clinical Target Volume: The Third Front. International Journal of Radiation Oncology Biology Physics, 2016, 95, 800-801.	0.4	6
59	Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to Illa Breast Cancer: A Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2016, 94, 118-125.	0.4	19
60	Novel and Highly Compressed Schedules for the Treatment of Breast Cancer. Seminars in Radiation Oncology, 2016, 26, 45-50.	1.0	0
61	Ultrashort Courses of Breast Radiotherapy. , 2016, , 363-372.		0
62	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC) Journal of Clinical Oncology, 2016, 34, TPS1097-TPS1097.	0.8	O
63	Ductal Carcinoma In Situ of the Breast. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 526-533.	0.6	12
64	Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials. Breast Journal, 2015, 21, 387-394.	0.4	5
65	Dexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma Cells. PLoS ONE, 2015, 10, e0135951.	1.1	26
66	Riluzole is a radioâ€sensitizing agent in an in vivo model of brain metastasis derived from <scp>GRM</scp> 1 expressing human melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 105-109.	1.5	16
67	In Regard to Vaidya etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 92, 952-953.	0.4	4
68	Genetic Syndromes and Radiotherapy in Breast Cancer. Medical Radiology, 2015, , 71-80.	0.0	0
69	Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1171-1180.	1.9	36
70	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypNO after neoadjuvant chemotherapy (NC) Journal of Clinical Oncology,	0.8	1
71	2015, 33, TPS111112-TPS11112. Optimization of Heart Block in the Left-Sided Whole Breast Radiation Treatments. Frontiers in Oncology, 2014, 4, 342.	1.3	4
72	Cardiac Avoidance in Breast Radiotherapy: Many Choices for a Worthwhile Objective. Frontiers in Oncology, 2014, 4, 269.	1.3	2

#	Article	IF	Citations
73	Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. Frontiers in Oncology, 2014, 4, 277.	1.3	79
74	Disruption of <scp>GRM</scp> 1â€mediated signalling using riluzole results in <scp>DNA</scp> damage in melanoma cells. Pigment Cell and Melanoma Research, 2014, 27, 263-274.	1.5	25
75	Magnetic Resonance-Guided Laser Ablation Improves Local Control for Postradiosurgery Recurrence and/or Radiation Necrosis. Neurosurgery, 2014, 74, 658-667.	0.6	132
76	Treatment Techniques to Reduce Cardiac Irradiation for Breast Cancer Patients Treated with Breast-Conserving Surgery and Radiation Therapy: A Review. Frontiers in Oncology, 2014, 4, 327.	1.3	30
77	Hypofractionated regional nodal irradiation for breast cancer: Examining the data and potential for future studies. Radiotherapy and Oncology, 2014, 110, 39-44.	0.3	30
78	Is excision alone adequate for low-risk DCIS of the breast treated with breast conserving therapy. Journal of Radiation Oncology, 2014, 3, 21-28.	0.7	2
79	Shortened Radiation Therapy Schedules for Early-Stage Breast Cancer: A Review of Hypofractionated Whole-Breast Irradiation and Accelerated Partial Breast Irradiation. Breast Journal, 2014, 20, 131-146.	0.4	17
80	Intraoperative Radiation Therapy in Breast Cancer: Not Ready for Prime Time. Annals of Surgical Oncology, 2014, 21, 351-353.	0.7	13
81	Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy. Radiotherapy and Oncology, 2014, 112, 279-283.	0.3	7
82	Patterns of intrafractional motion and uncertainties of treatment setup reference systems in accelerated partial breast irradiation for right- and left-sided breast cancer. Practical Radiation Oncology, 2014, 4, 6-12.	1.1	14
83	Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiotherapy and Oncology, 2014, 112, 9-16.	0.3	137
84	Importance of initial aggressive treatment for pineal parenchymal tumor of intermediate differentiation: A case report and review of literature. Practical Radiation Oncology, 2013, 3, e29-e34.	1.1	5
85	Threeâ€year outcomes of a once daily fractionation scheme for accelerated partial breast irradiation (<scp>APBI</scp>) using 3â€D conformal radiotherapy (3Dâ€ <scp>CRT</scp>). Cancer Medicine, 2013, 2, 964-971.	1.3	12
86	Lumpectomy Closure Technique Does Not Affect Dosimetry in Patients Undergoing External-Beam-Based Accelerated Partial Breast Irradiation. Annals of Surgical Oncology, 2013, 20, 1323-1328.	0.7	6
87	On the Merits and Limitations of Whole-Brain Radiation Therapy. Journal of Clinical Oncology, 2013, 31, 11-13.	0.8	34
88	When Retrospective Comparative Effectiveness Research Hinders Science and Patient-Centered Care. Journal of Clinical Oncology, 2013, 31, 2226-2227.	0.8	5
89	The Relative Benefits of Tamoxifen in Older Women with T1 Early-Stage Breast Cancer Treated with Breast-Conserving Surgery and Radiation Therapy. Breast Journal, 2013, 19, n/a-n/a.	0.4	5
90	On the road to intraoperative radiotherapy: more 'proceed with caution' signs. Oncology, 2013, 27, 113-4, 122.	0.4	9

#	Article	IF	Citations
91	Utilization of Breast Conserving Therapy in Stages 0, I, and II Breast Cancer Patients in New Jersey. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 130-135.	0.6	6
92	Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer Treated with Adjuvant Radiotherapy in Combination with Pazopanib. ISRN Oncology, 2012, 2012, 1-5.	2.1	12
93	Factors Associated With Optimal Long-Term Cosmetic Results in Patients Treated With Accelerated Partial Breast Irradiation Using Balloon-Based Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 512-518.	0.4	20
94	Ultra-Short Courses of Adjuvant Breast Radiotherapy: Promised Land or Primrose Path?. International Journal of Radiation Oncology Biology Physics, 2012, 82, 499-501.	0.4	6
95	Local Control, Toxicity, and Cosmesis in Women >70 Years Enrolled in the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial. International Journal of Radiation Oncology Biology Physics, 2012, 84, 323-330.	0.4	31
96	Issues in the Curative Therapy of Breast Cancer in Elderly Women. Seminars in Radiation Oncology, 2012, 22, 295-303.	1.0	5
97	Technical Note: Contrast solution density and cross section errors in inhomogeneity-corrected dose calculation for breast balloon brachytherapy. Medical Physics, 2012, 40, 011703.	1.6	1
98	Ultrashort courses of adjuvant breast radiotherapy. Cancer, 2012, 118, 1962-1970.	2.0	13
99	Weight Gain in Advanced Non–Small-Cell Lung Cancer Patients During Treatment With Split-Course Concurrent Chemoradiotherapy Is Associated With Superior Survival. International Journal of Radiation Oncology Biology Physics, 2011, 81, 985-991.	0.4	19
100	Clinicopathologic Presentation of Asian-Indian American (AIA) Women with Stage 0, I & Deast Cancer. Journal of Immigrant and Minority Health, 2011, 13, 42-48.	0.8	2
101	Comparison of radiationâ€induced fatigue across 3 different radiotherapeutic methods for early stage breast cancer. Cancer, 2011, 117, 4116-4124.	2.0	33
102	Evaluation of Acute Locoregional Toxicity in Patients With Breast Cancer Treated With Adjuvant Radiotherapy in Combination With Bevacizumab. International Journal of Radiation Oncology Biology Physics, 2011, 79, 408-413.	0.4	21
103	Intrafractional Target Motions and Uncertainties of Treatment Setup Reference Systems in Accelerated Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1549-1556.	0.4	43
104	Cystic Lesions of the Pancreas. American Journal of Roentgenology, 2011, 196, W668-W677.	1.0	33
105	Prospective Gating With 320-MDCT Angiography: Effect of Volume Scan Length on Radiation Dose. American Journal of Roentgenology, 2011, 196, 407-411.	1.0	27
106	Riluzole Enhances Ionizing Radiation–Induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 <i>In Vitro</i> and <i>In Vivo</i> Clinical Cancer Research, 2011, 17, 1807-1814.	3.2	37
107	Improvement in Interobserver Accuracy in Delineation of the Lumpectomy Cavity Using Fiducial Markers. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1127-1134.	0.4	44
108	Breast-Conserving Therapy in Women with BRCA1/BRCA2-Associated Breast Cancer. Current Breast Cancer Reports, 2010, 2, 90-95.	0.5	0

#	Article	IF	CITATIONS
109	Hypofractionation in adjuvant breast radiotherapy. Breast, 2010, 19, 168-171.	0.9	12
110	Permanent Iodine-125 Interstitial Planar Seed Brachytherapy for Close or Positive Margins for Thoracic Malignancies. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1114-1120.	0.4	26
111	Palonosetron—A Single-Dose Antiemetic Adjunct for Hepatic Artery Radioembolization: A Feasibility Study. CardioVascular and Interventional Radiology, 2009, 32, 47-51.	0.9	0
112	Evaluation of Four Volume-Based Image Registration Algorithms. Medical Dosimetry, 2009, 34, 317-322.	0.4	9
113	Challenges in Personalizing Decisions on Whole, Partial or No Breast Irradiation and Extent of Surgery for Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2658-2658.	0.7	0
114	Factors Associated with Optimal Cosmetic Results at 36ÂMonths in Patients Treated with Accelerated Partial Breast Irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite® Breast Brachytherapy Registry Trial. Annals of Surgical Oncology, 2009, 16, 2450-2458.	0.7	43
115	Key points in repeat breast-conservation therapy. Oncology, 2009, 23, 940-1.	0.4	O
116	Dose volume histogram analysis of normal structures associated with accelerated partial breast irradiation delivered by high dose rate brachytherapy and comparison with whole breast external beam radiotherapy fields. Radiation Oncology, 2008, 3, 39.	1.2	34
117	Accelerated partial breast irradiation using the MammoSite® device. Nature Clinical Practice Oncology, 2007, 4, 324-325.	4.3	0
118	Inherent change in MammoSite applicator three-dimensional geometry over time. Radiation Oncology, 2007, 2, 37.	1.2	1
119	Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiotherapy and Oncology, 2006, 81, 163-167.	0.3	92
120	A dosimetric comparison of three-dimensional conformal, intensity-modulated radiation therapy, and MammoSite partial-breast irradiation. Brachytherapy, 2006, 5, 183-188.	0.2	37
121	Positron Emission Tomography Demonstrates Radiation-Induced Changes to Nonirradiated Lungs in Lung Cancer Patients Treated With Radiation and Chemotherapy. Chest, 2005, 128, 1448-1452.	0.4	33
122	BRCA Status, Molecular Markers, and Clinical Variables in Early, Conservatively Managed Breast Cancer. Breast Journal, 2003, 9, 167-174.	0.4	11
123	Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet, The, 2002, 359, 1471-1477.	6.3	290
124	Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clinical Cancer Research, 2002, 8, 540-8.	3.2	64
125	The Location of Contralateral Breast Cancers After Radiation Therapy. Breast Journal, 2001, 7, 331-336.	0.4	7
126	Adenoid cystic carcinoma: A retrospective clinical review. International Journal of Cancer, 2001, 96, 149-158.	2.3	238